Sun Pharma acquires Japan’s Pola Pharma

Sun Pharma has entered into a definitive agreement to acquire Pola Pharma, which is engaged in research and development, manufacture, sale, and distribution of branded, and generic products in Japan. It has two manufacturing facilities in Saitama with capabilities to manufacture topical products and injectables. The acquisition of 100 percent shares of Pola Pharma Inc., Japan by the company’s wholly owned subsidiary has been concluded. Sun Pharma had forayed into the Japanese prescription market in 2016 with the acquisition of 14 established prescription brands from Novartis.